Therapeutic Efficacy Analysis of Allogeneic Peripheral Blood Hematopoietic Stem Cell Transplantation for 14 Adult Patients with T Lymphoblastic Lymphoma.
- Author:
Hua-Ping WEI
1
;
Xiao-Li ZHAO
2
;
Wen-Rong HUANG
1
;
Jian BO
1
;
Hong-Hua LI
1
;
Yu ZHAO
1
;
Hai-Yan ZHU
1
;
Yu JIN
1
;
Lei YUAN
1
;
Li WANG
1
;
Zhen-Yang GU
1
;
Nan YANG
1
;
Fei-Yan WANG
1
;
Quan-Shun WANG
1
;
Dai-Hong LIU
1
;
Li YU
1
;
Chun-Ji GAO
3
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Disease-Free Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Neoplasm Recurrence, Local; Peripheral Blood Stem Cell Transplantation; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; therapy; Retrospective Studies; Survival Rate
- From: Journal of Experimental Hematology 2016;24(2):433-437
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the therapeutic efficacy of allogeneic peripheral blood hematopoietic stem cell transpdantation (allo-HSCT) for T lymphoblastic lymphoma (T-LBL).
METHODSThe clinical data of 14 adult patients with T-LBL treated with allo-HSCT were collected, the hematopoietic reconstruction, survival and relapse, as well as overall survival (OS) rate, event-free survival (EFS) rate of 1, 3 and 5 years were analysed retrospectively.
RESULTSAll the patients were engrafted with neutrophil successfully, the median time of absolute neutrophil count >0.5 × 10(9)/L was 13 (10-19) d; 13 patients were engrafted with platelets successfully, the median time of Plt count >20 × 10(9)/L was 17 (12-62) days. The acute GVHD occurred in 6 patients, but among them only 1 case with 3 grade of aGVHD; out of 14 patients, 5 developed chronic GVHD. The transplant-related mortality at 100 days was 7.1% (1/14), mainly from coronary heart disease and pulmonary infection. The median follow-up time was 26.5 months, the estimated 1, 3 and 5 year OS rate was 85.7%, 47.6% and 38.1%, respectively, and estimated 1, 3 year EFS rate was 85.7%, 34.4% and 34.1%, respectively. The relapse rate was 42.8% (6/14) and the median relapse time was 22.5% months after transplantation. Up to now, 7 patients still survive, 1 patient out of them have survived for 103 months.
CONCLUSIONThe allo-HSCT is a safe and effective method for treatment of T-LBL.